CUV.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 09:10):

Stats
Dzisiejszy wolumen	45 805.00
Średni wolumen	139 228
Kapitalizacja rynkowa	744.54M
EPS	$0 ( 2024-02-21 )
Last Dividend	$0.0500 ( 2023-09-05 )
Next Dividend	$0 ( N/A )
P/E	26.07
ATR14	$0.0210 (0.14%)

Wolumen Korelacja

Długi: 0.03 (neutral)

Krótki: -0.36 (neutral)

Signal:(70.379) Neutral

Clinuvel Pharmaceuticals Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Clinuvel Pharmaceuticals Korelacja - Waluta/Towar

-0.41
( neutral )

-0.55
( weak negative )

0.00
( neutral )

-0.53
( weak negative )

-0.45
( neutral )

-0.56
( weak negative )

Clinuvel Pharmaceuticals Finanse

Annual	2023
Przychody:	$78.32M
Zysk brutto:	$50.59M (64.59 %)
EPS:	$0.620

FY	2023
Przychody:	$78.32M
Zysk brutto:	$50.59M (64.59 %)
EPS:	$0.620

FY	2022
Przychody:	$65.72M
Zysk brutto:	$46.62M (70.93 %)
EPS:	$0.420

FY	2021
Przychody:	$47.98M
Zysk brutto:	$43.26M (90.16 %)
EPS:	$0.513

Financial Reports:

No articles found.

Clinuvel Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0.0400 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0.0500 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Clinuvel Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.00 - Stable (0.02%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.0200	2018-09-21
Last Dividend	$0.0500	2023-09-05
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	6	--
Total Paid Out	$0.185	--
Avg. Dividend % Per Year	0.00%	--
Score	2.86	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.00
Div. Directional Score	7.68	--

Next Divdend (Est)
(2024-07-01)

$0.0598 Estimate 3.10 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.86

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
SEK.AX	Ex Dividend Knight	2023-09-06	Annually	0.00%
CCP.AX	Ex Dividend Knight	2023-09-18	Annually	0.00%
MEA.AX	Ex Dividend Knight	2023-08-30	Annually	0.00%
TLS.AX	Ex Dividend Knight	2023-08-30	Semi-Annually	0.00%
CUV.AX	Ex Dividend Junior	2023-09-05	Annually	0.00%
NIC.AX	Ex Dividend Junior	2023-08-03	Semi-Annually	0.00%
FGG.AX	Ex Dividend Junior	2023-10-05	Annually	0.00%
PPC.AX	Ex Dividend Knight	2023-09-08	Semi-Annually	0.00%
ARG.AX	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%
IFL.AX	Ex Dividend Junior	2023-09-07	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.371	1.500	2.58	3.86	[0 - 0.5]
returnOnAssetsTTM	0.142	1.200	5.25	6.30	[0 - 0.3]
returnOnEquityTTM	0.176	1.500	9.16	10.00	[0.1 - 1]
payoutRatioTTM	0.0819	-1.000	9.18	-9.18	[0 - 1]
currentRatioTTM	6.86	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	6.38	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.321	1.500	3.77	5.66	[0.2 - 2]
debtRatioTTM	0.00505	-1.500	9.92	-10.00	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.725	2.00	9.64	10.00	[0 - 20]
debtEquityRatioTTM	0.00598	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.621	1.000	2.99	2.99	[0.2 - 0.8]
operatingProfitMarginTTM	0.483	1.000	2.33	2.33	[0.1 - 0.6]
cashFlowToDebtRatioTTM	39.55	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.384	0.800	-0.775	-0.620	[0.5 - 2]
Total Score				10.36

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	24.70	1.000	7.61	0	[1 - 100]
returnOnEquityTTM	0.176	2.50	9.46	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.725	2.00	9.76	10.00	[0 - 30]
dividendYielPercentageTTM	0.336	1.500	1.588	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.843	2.00	9.72	10.00	[0 - 30]
payoutRatioTTM	0.0819	1.500	9.18	-9.18	[0 - 1]
pegRatioTTM	-0.831	1.500	-8.87	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.520	1.000	10.00	0	[0.1 - 0.5]
Total Score				5.00

Clinuvel Pharmaceuticals

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.